Navigation Links
International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development

NEWARK, Del., Sept. 12 /PRNewswire-USNewswire/ -- Leading scientists from around the world will meet in Wilmington, Delaware next week to discuss innovative approaches for producing life-saving vaccines and antibodies. More than 125 scientists and business leaders will be participating in "New Cells for New Vaccines II: Focus on Respiratory Virus Diseases" on September 17-19 at the Hotel du Pont. The international scientific workshop is being organized by the Fraunhofer USA Center for Molecular Biotechnology (CMB) and InB:Biotechnologies, Inc. of Newark, Delaware, under the auspices of the International Association for Biologicals (IABS).

According to Dr. Vidadi Yusibov, Executive Director of the Fraunhofer USA Center for Molecular Biotechnology, "The past fifty years have seen an increase in the types of cells that can be used for vaccine and antibody production, however, there remains a need for new cell substrates that can provide safer, faster and more cost effective production alternatives to current techniques, especially with the potential threat of an influenza pandemic."

"A key aspect of the success and viability of a vaccine development project is the choice of an appropriate cell substrate," said Dr. Geoffrey Schild, Chief Scientific Officer of InB:Biotechnologies and a Director of IABS. "The advantages of plant, animal and insect cell systems are increasingly being recognized and many projects are in progress internationally, including development of respiratory virus, cervical cancer, anthrax and malaria vaccines, as well as therapeutic antibodies to treat influenza infections."

New Cells for New Vaccines II: Focus on Respiratory Virus Diseases will be of interest to scientists and business leaders in the biotechnology and pharmaceutical industry involved in vaccine development and production, as well as public health officials, medical and veterinary experts. More details and registration information are available on the meeting web site (

About Fraunhofer USA Center for Molecular Biotechnology:

The mission of Fraunhofer USA CMB is to develop safe and effective vaccines targeting infectious diseases and autoimmune disorders. CMB's technology provides a safe, rapid and economical alternative for vaccine production. Fraunhofer USA CMB is part of Fraunhofer USA, Inc., a non-profit research and development corporation, with headquarters in Michigan. It operates through technology centers that are partnered with major research universities in the United States and also with parent research institutes in Germany.

For more information, contact: Dale Ervin, Fraunhofer USA CMB at 302-369-1708 or

SOURCE Fraunhofer USA
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Olympics of biotechnology has international flavor
2. Traffic data firm navigates international business
3. Catalyst International profit exceeds expectations
4. Lack of broadband hamstrings international videoconferencing
5. 30 days to success: Three simple steps to create your own international startup
6. TEKLYNX International announces new RFID software
7. Ruling enforces international trademark electronic filing requirements
8. Eleftheriou to lead Catalyst International
9. Internet trademark war goes international
10. International eyes drawn to Madisons games research
11. Plexus and SRI International team up to offer medical product development
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
(Date:3/18/2016)... 18, 2016 --> ... ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance ... in the border security market and the continuing migration crisis ... Europe has led visiongain to publish this ... --> defence & security companies in the ...
Breaking Biology News(10 mins):